2001 Cannabinoids Clinical Trials Sleep 
CannaMD
AUGUST 26, 2020
A new review published by scientific journal, Pharmacology Biochemistry and Behavior , has found that marijuana cannabinoid, CBD, is a “promising” therapy for treating cocaine dependence. Exploring alternative therapies, researchers turned their attention to marijuana cannabinoid, cannabidiol – more commonly referred to as CBD.
The Cannigma
JANUARY 13, 2023
The ECS touches on nearly every biological function you have, including sleep, pain, appetite, body temperature, immune function, memory, and hormone regulation. Since pain and nausea are two of the most common symptoms of migraines, this cannabinoid is of great scientific interest in helping people who suffer from migraines.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Cannabis Law Report
AUGUST 2, 2021
OTCQB: SPRCY ) a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, today announced positive top-line results for its proprietary compound, SCI-160 in a controlled pre-clinical trial on neuropathic and post-operative pain. TEL AVIV, Israel , Aug.
Cannabis Law Report
NOVEMBER 24, 2021
The recreational use of cannabis is well known and attributed to its power as a psychotropic plant, specifically due to the cannabinoid tetrahydrocannabinol (THC). Only one article appeared in the MJA in 2000 and again in 2001. Less frequent were references to multiple sclerosis, anxiety and depression, sleep, and HIV.
Cannabis Law Report
JUNE 4, 2021
Rick, and MAPS, have published hundreds of research papers, articles, and reports over the past several decades in addition to participation in dozens of clinical trials and international studies. Rick Doblin, Ph.D, in/rickdoblin/ [link]. Drug Science. Matthew Johnson. Johns Hopkins University. in/ingmargorman/ [link].
Expert insights. Personalized for you.
98 
Let's personalize your content